Kenvue Inc. (KVUE) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

BULLISH

Options traders are showing increased activity in Kenvue, with elevated volume and open interest suggesting anticipation of a significant price swing. This heightened options trading could signal upcoming volatility or reflect market sentiment on future performance, prompting investors to watch for any catalysts that might drive such a move.

Market Data

KVUE Stock Snapshot

Kenvue Inc. · Consumer Defensive · kenvue.com

Kenvue Inc. is a global consumer health company with a diverse portfolio of well-known brands across three primary segments. The company's Self Care division focuses on over-the-counter medications and related products, including leading brands like Tylenol and Benadryl. Kenvue's Skin Health and Beauty segment features popular brands such as Neutrogena and Aveeno, while the Essential Health segment provides essential personal care products like Johnson's baby care and Band-Aid bandages. Operating internationally across multiple regions, Kenvue was established in 2022 and is headquartered in Summit, New Jersey, offering a broad range of consumer health solutions.

KVUE is currently trading at $17.53, giving Kenvue Inc. a market cap of 33.75B and a P/E ratio of 23.0. Today's range spans $17.40–$17.80, with shares opening at $17.50 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD) with a news sentiment reading of 74/100.

Over the past year KVUE has traded between $14.02 and $25.17 - the current price is +25.0% off the 52-week low and -30.4% from the high. 21 analysts cover the stock with a Hold consensus and a mean 12-month target of $19.58 (range $18.00–$23.00), implying upside of +11.7%.

KVUE trades at $17.53 (in the lower half of its 52-week range within $14.02–$25.17) - and the HOLD signal (59/100) reflects a market that's fairly priced relative to near-term expectations rather than one that's mispriced in either direction. (P/E: 23.0) At 33.75B in Consumer Defensive market cap, bullish sentiment (74/100) confirms the lack of near-term narrative catalyst. The thesis is intact; the timing is patient.

KVUE|EarningsKenvue Inc.

Earnings Summary

Kenvue Inc. is a global consumer health company operating in the Consumer Defensive sector, specifically within the Household & Personal Products industry. The company boasts a diverse portfolio of well-known brands across its Self Care, Skin Health and Beauty, and Essential Health segments, including prominent names like Tylenol, Neutrogena, and Band-Aid bandages, offering a broad range of consumer health solutions internationally. In its most recent reported quarters, Kenvue demonstrated a trend of exceeding earnings per share estimates, with actual EPS of $0.26 in Q4 2024 and $0.24 in Q1 2025, both surpassing their respective estimates. Revenue also saw an increase, rising from $3.66 billion in Q4 2024 to $3.74 billion in Q1 2025. This performance suggests a positive, albeit moderate, growth trajectory in both earnings and revenue in the immediate preceding periods. Looking at a slightly longer historical streak, Kenvue has shown a pattern of beating analyst expectations for earnings per share in recent quarters, including Q4 2024, Q1 2025, Q2 2025, and Q3 2025, indicating a consistent ability to meet or exceed profit forecasts. Revenue figures have also generally trended upwards over these periods, supporting the earnings beats. Recent news highlights Kenvue's scientific advancements in skincare and sun care, showcased at the American Academy of Dermatology Annual Meeting, which could bolster its market position. However, some analyst adjustments, such as Citigroup and UBS lowering price targets, suggest a cautious near-term outlook, despite the company's defensive sector positioning and dividend growth. Investors will be watching for the impact of these scientific innovations on future sales and for any further analyst commentary that might clarify market sentiment. Key will be observing the company's ability to maintain its earnings beat streak and revenue growth momentum in the upcoming quarters, especially as its portfolio integration with Kimberly-Clark is slated for the second half of 2026.

Earnings | EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$0.26	-	-
Q4'25	$0.23	$0.27	+19.7%
Q3'25	$0.26	$0.28	+5.7%
Q2'25	$0.28	$0.29	+2.2%
Q1'25	$0.23	$0.24	+5.4%
Q4'24	$0.26	$0.26	+1.5%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$3.8B	-	-
Q4'25	$3.8B	$3.8B	+0.7%
Q3'25	-	$3.8B	-
Q2'25	-	$3.8B	-
Q1'25	-	$3.7B	-
Q4'24	-	$3.7B	-

Technical Score (1D)

BUY

News Sentiment

BULLISH

Market Data

KVUE Stock Snapshot

Kenvue Inc. · Consumer Defensive · kenvue.com

News Sentiment Analysis

Sentiment gathered from recent headlines

74/100

Strong NegativeNeutralStrong Positive

BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Analysis of Kenvue's options market indicates a notable level of activity, suggesting traders are positioning for a substantial price swing. The volume and open interest in specific options contracts point towards expectations of volatility. This heightened options trading could precede a significant event or reflect market sentiment regarding future performance.

What did this article say?

Kimberly-Clark has announced the organizational structure and key leadership appointments that will take effect following its acquisition of Kenvue Inc. (KVUE). The new structure aims to foster agility and speed, aligning teams around a shared ownership mindset. This move signals the integration planning is progressing as the deal nears completion.

What did this article say?

Citigroup has revised its price target for Kenvue (KVUE), lowering it from $20 to $19. The firm has reiterated its 'Neutral' rating on the stock. This adjustment suggests a cautious outlook from the analyst, reflecting current market conditions or company-specific factors without a strong conviction for significant upside or downside.

What did this article say?

Barclays has adjusted its price target for Kenvue (KVUE), lowering it from $19 to $18. The firm has maintained its Equalweight rating on the stock. This revision suggests a cautious outlook from the analyst, reflecting potential shifts in valuation or market perception for the consumer health company.

What did this article say?

Representative Gilbert Ray Cisneros, Jr. disclosed a sale of Kenvue Inc. (KVUE) stock, with transactions ranging between $1,001 and $15,000. This trade occurred on March 13th, with the filing made on April 7th. The disclosure adds to a series of other trades made by the representative in various other companies during the same period.

What did this article say?

UBS has lowered its price target for Kenvue (KVUE) from $19 to $18, while reiterating a Neutral rating. This adjustment reflects a recalibration of the firm's valuation expectations for the consumer health company. The move suggests a cautious outlook from UBS regarding KVUE's near-term prospects.

What did this article say?

Kenvue's leading brands, including Neutrogena and Aveeno, presented new science-backed skincare and haircare advancements at the American Academy of Dermatology Annual Meeting. The company highlighted its commitment to sun care innovation, particularly focusing on advanced UV protection technologies like BEMT. These developments aim to strengthen Kenvue's position in the dermatology and consumer health markets, potentially influencing its investment profile.

What did this article say?

Kenvue Inc. experienced a decline in its stock price on Thursday, underperforming the broader market. This movement suggests potential short-term headwinds or sector-specific pressures affecting the company's valuation.

What did this article say?

Kenvue (KVUE) has demonstrated relative stability, with its stock experiencing a smaller decline compared to the broader S&P 500 over the past month. This resilience is attributed to its position within the healthcare sector, historically known for weathering economic downturns more effectively. The company's consistent dividend increases, a hallmark of its financial strength, further support its appeal.

What did this article say?

Kenvue (KVUE) shows signs of technical support with a hammer chart formation following recent price declines. This pattern, coupled with upward revisions in analyst earnings estimates, suggests a potential near-term turnaround. The confluence of technical indicators and analyst sentiment points to a more favorable outlook for the stock.

KVUE|EarningsKenvue Inc.

Earnings Summary

Earnings | EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$0.26	-	-
Q4'25	$0.23	$0.27	+19.7%
Q3'25	$0.26	$0.28	+5.7%
Q2'25	$0.28	$0.29	+2.2%
Q1'25	$0.23	$0.24	+5.4%
Q4'24	$0.26	$0.26	+1.5%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$3.8B	-	-
Q4'25	$3.8B	$3.8B	+0.7%
Q3'25	-	$3.8B	-
Q2'25	-	$3.8B	-
Q1'25	-	$3.7B	-
Q4'24	-	$3.7B	-

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

KVUE·Kenvue Inc.

KVUE Stock Snapshot

Earnings | EPS

Revenue

KVUE·Kenvue Inc.

KVUE Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Earnings | EPS

Revenue

News Sentiment Analysis

Recent News Coverage

KVUE·Kenvue Inc.

KVUE Stock Snapshot

Earnings | EPS

Revenue

KVUE·Kenvue Inc.

KVUE Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Earnings | EPS

Revenue

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More